Clinical Analysis Of Treating 4 Cases Of Cervical Neuroendocrine Carcinoma

Objective:Analysis of the cervix neuroendocrine carcinoma four examples of clinical characteristics, so as to improve the clinical features of the disease awareness.Methods:Analysed the statistics who were treated in the first affiliated hospital of Dalian Medical University during January 2005 to December 2010, 4 cases were confirmed by pathology cervical neuroendocrine carcinoma patients for clinical data, as its onset ages, clinical manifestations, without lymph node metastasis and pathological characteristics, treatments and prognosis for analysis.Results: (1)The four examples of Cervix nerve internal secretion cancer patient take account of 1.17% of the cervical cancer over the same period,among them, there are 3 examples of patients with small cell neuroendocrine carcinoma amount to 0.88% of the cervical cancer over the same period,the incidence of large cell neuroendocrine carcinoma of the cervix is 0.30%; small cell neuroendocrine carcinoma of cervix 3 patients with an average age 51.67 years old, large cell neuroendocrine carcinoma of the cervix 1 patients age was 55; 4 example cervical neuroendocrine carcinoma patients 3 cases of IB1period (75%), and 1 case ofⅡB(25%). One small cell neuroendocrine carcinoma of the cervix in 2 cases,ⅠB1periodⅡB period, 1 case with large cell neuroendocrine carcinoma 1 case ofⅠB1 period;(2)Cervix small cell neuroendocrine carcinoma patients with common symptom is contact hemorrhages in 2 cases (66.67%), vaginal bleeding after menopause in 1 case (33.33%); Large cell neuroendocrine carcinoma were the main symptoms vaginal bleeding ; (3)4 example cervical neuroendocrine carcinoma patients were no distant organ metastases. Small cell neuroendocrine carcinoma cervical lymph node metastasisⅠB1 period 1 case with 33.33%), cervix large cell neuroendocrine carcinoma patients without lymph node metastasis. Four examples patients with cervical neuroendocrine carcinoma in immunohistochemical specific antibodiesNSEpositive (100%), CgA positive (75%), Syn positive (75%), CKl8 positive (50%) are two and two kinds of above markers positive;(4)Cervix small cell neuroendocrine carcinoma patients with surgical operationⅠB1 period and postoperative adjuvant radiation and chemotherapy, radiotherapyⅡB period use; Cervix large cell neuroendocrine carcinoma patients with surgical operationⅠB1 period and postoperative adjuvant radiation therapy; 2 cases of small cell neuroendocrine carcinoma patients respectively of chemotherapy regimens for platinum+VP-16(DDP+VP-16 PE) scheme chemotherapy, irinotecan-based+cisplatin chemotherapy (CPT-11+DDP PC) scheme,paclitaxel plus cisplatin (TAT + DDP TP) scheme;(5)4 example cervical small cell neuroendocrine carcinoma patients were during follow-up (100%).Conclusion:(1)Cervix neuroendocrine carcinoma are extremely rare, at time of diagnosis for more early;(2)Cervix neuroendocrine carcinoma with the clinical characteristics of cervical squamous cell carcinoma, no obvious difference in contact hemorrhages, vaginal drainage major clinical manifestations;(3)Cervix neuroendocrine carcinoma compared with squamous cell carcinoma of the uterine cervix malignant degree is high, easy to occur pelvic lymph node metastasis;(4)The cerix neuroendocrine carcinoma diagnosis can only rely on pathological and immunohistochemical;(5)Cervix neuroendocrine carcinoma operation mode and cervical squamous cell carcinoma, surgery need no difference adjuant radiation and chemotherapy, choose PE/PC/TP scheme chemotherapy。...